Aurobindo Pharma バランスシートの健全性
財務の健全性 基準チェック /56
Aurobindo Pharmaの総株主資本は₹308.8B 、総負債は₹80.9Bで、負債比率は26.2%となります。総資産と総負債はそれぞれ₹480.9Bと₹172.1Bです。 Aurobindo Pharmaの EBIT は₹49.8Bで、利息カバレッジ比率63.2です。現金および短期投資は₹68.7Bです。
主要情報
26.2%
負債資本比率
₹80.91b
負債
インタレスト・カバレッジ・レシオ | 63.2x |
現金 | ₹68.68b |
エクイティ | ₹308.85b |
負債合計 | ₹172.09b |
総資産 | ₹480.94b |
財務の健全性に関する最新情報
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Recent updates
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
Nov 12Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price
Oct 20Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Sep 10This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20財務状況分析
短期負債: AUROPHARMAの 短期資産 ( ₹262.3B ) が 短期負債 ( ₹143.4B ) を超えています。
長期負債: AUROPHARMAの短期資産 ( ₹262.3B ) が 長期負債 ( ₹28.7B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: AUROPHARMAの 純負債対資本比率 ( 4% ) は 満足できる 水準であると考えられます。
負債の削減: AUROPHARMAの負債対資本比率は、過去 5 年間で37.2%から26.2%に減少しました。
債務返済能力: AUROPHARMAの負債は 営業キャッシュフロー によって 十分にカバーされていません ( 19.6% )。
インタレストカバレッジ: AUROPHARMAの負債に対する 利息支払い は EBIT ( 63.2 x coverage) によって 十分にカバーされています。